$3.24
-0.1590 ( -4.68% ) 282.5K
Clinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034)DetailsCancer, Colorectal cancer | Phase 2 |
| Botensilimab (AGEN1181) (anti-CLTA-4)DetailsCancer, Melanoma, Pancreatic cancer | Phase 2 |
| AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapiesDetailsCancer, Non-small cell lung carcinoma, Solid tumor/s, Lung cancer | Phase 2 |
| Botensilimab (AGEN1181) + balstilimabDetailsCancer, Sarcoma | Phase 1b |
| Botensilimab (AGEN1181)DetailsCancer, Non-small cell lung carcinoma | Phase 1b |
| Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034)DetailsCancer, Ovarian cancer | Phase 1b |
| AGEN2373 w/ Botensilimab (AGEN1181)DetailsSolid tumor/s, Cancer, Melanoma | Phase 1b |
| AGEN1571 w/ Botensilimab (AGEN1181) & Balstilimab (AGEN2034)DetailsSolid tumor/s, Cancer | Phase 1 |
| Balstilimab (AGEN2034)DetailsCancer, Cervical cancer | Failed |
| Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4)DetailsCancer, Cervical cancer | Failed |
| Botensilimab (AGEN1181) (anti-CLTA-4)DetailsCancer, Pancreatic cancer, Melanoma | Phase 2 |
| Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034)DetailsColorectal cancer , Cancer | Phase 2 |
Market Data
| Open | $3.24 |
| Previous Close | $3.40 |
| Volume | 282.5K |
| Market Cap | $134.09M |
| Day Range | $3.23 - $3.42 |
| 52 Week Range | $2.71 - $7.34 |
| Shares Outstanding | 41.64M |
| Change % | -4.68% |
| Net Change | ▼ -0.1590 |
| Insider Ownership | -0.04% |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| IPO Year | 2000 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased: 95,345.82
| Date | Type | Amount Purchased | Purchaser |
|---|---|---|---|
| 2024-02-12 | Sale | -19778.00 | ARMEN GARO H |
| 2024-01-29 | Sale | -22475.00 | ARMEN GARO H |
| 2024-01-16 | Sale | -23177.00 | ARMEN GARO H |
| 2024-01-04 | Sale | -30956.38 | WIINBERG ULF |
| 2024-01-04 | Sale | -11325.50 | Wright Timothy |
| 2024-01-04 | Sale | -25671.14 | Hirsch Susan B |
| 2024-01-03 | Sale | -23453.00 | ARMEN GARO H |
| 2023-12-18 | Sale | -23453.00 | ARMEN GARO H |
| 2023-12-04 | Sale | -20727.00 | ARMEN GARO H |
| 2023-11-20 | Sale | -23511.00 | ARMEN GARO H |
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Apr 06, 2026 |
| 4 | Insider transactions | 1 | Apr 02, 2026 |
| schedule | Other | 1 | Mar 26, 2026 |
| 8-k | 8K-related | 9 | Mar 26, 2026 |
| 4 | Insider transactions | 1 | Mar 24, 2026 |
| 8-k | 8K-related | 11 | Mar 16, 2026 |
| 10-k | Annual reports | 127 | Mar 16, 2026 |
| 4 | Insider transactions | 1 | Mar 09, 2026 |
| 4 | Insider transactions | 1 | Feb 24, 2026 |
| 4 | Insider transactions | 1 | Feb 09, 2026 |
Latest News
Hello, I'm RedChat, your AI assistant for AGEN